Inhibiting the release of exosomal oncomiRs, or increasing the effect of tumor suppressor miRNAs, could also play a synergic role in immunotherapy: for example, it has been shown that the inhibition of miR-23a-3p in HCC cancer cells could prevent their exosomal release and the consequent expression of PD-L1 in macrophages (92). The gene discussed is CD274; the disease is neoplasm.